For patients with BRAF V600E-mutant metastatic colorectal cancer (mCRC), encorafenib + cetuximab (EC) plus standard chemotherapy (modified folinic acid [or levofolinate], fluorouracil, and oxaliplatin ...

The firm recorded Q4 oncology revenues of $4.06 billion compared to $3.19 billion in the same period last year.

Q4 2024 Earnings Conference Call February 4, 2025 10:30 AM ETCompany ParticipantsFrancesca DeMartino - Senior Vice President, ...

Pfizer's late-stage BRAF V600E-mutant mCRC study of the Braftovi combo regimen meets its other dual primary endpoint of PFS ...

CEO Albert Bourla says Pfizer has met the strategic goals it had set for itself in 2024, and that it was ‘executing transformative changes.’ ...

Pfizer has announced that its Braftovi (encorafenib) regimen significantly improved both progression-free and overall ...

Pfizer Inc. (NYSE: PFE) today announced positive topline results from the progression-free survival (PFS) analysis of the Phase 3 BREAKWATER study of ...

Pfizer only picked up an accelerated approval from the FDA for its Braftovi-based combination regimen for colorectal cancer ...

Analysts expect the New York-based company to report quarterly earnings at 46 cents per share, up from 10 cents per share in ...

The CEO said last month that the drugmaker had cut costs, revamped its sales operation, and made other big fixes.

The results could sway U.S. regulators to convert Braftovi’s accelerated clearance in colorectal tumors into a full approval ...